ReviewSeminars in radiation oncology2008
Tissue microarrays in clinical oncology.
Review in Seminars in radiation oncology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02810405 (Collection of Tissue Blocks or Slides From Patients With Cancer), which is not on this map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Collection of Tissue Blocks or Slides From Patients With Cancer
Who cites it
52 citing papers in PubMed, 141 citations in OpenAlex.
- MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer.International journal of radiation oncology, biology, physics · 2019Trial
- Integrated bioinformatics and molecular docking identify novel key genes, pathways, and potential candidate drugs in papillary thyroid carcinoma.Journal, genetic engineering & biotechnology · 2026Article
- Ectonucleotidases CD39 and CD73 expression levels are independent and inverse predictors of survival in muscle-invasive bladder cancer.The journal of pathology. Clinical research · 2026Article
- MIMIC: a flexible pipeline to register and summarize IMC-MSI experiments.Communications biology · 2026Article
- Identification and Validation of Prognostic Biomarker Signatures Associated with Overall Survival in Colorectal Cancer: Evidence from Bioinformatics Analysis and an in vivo Study.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- HER2 as a molecular trojan horse in prostate cancer: mechanistic insights and therapeutic unlocks.Molecular biology reports · 2025Review
- Association of EnterotoxigenicCancers · 2025Article
- Multiplex Immunofluorescence Reveals Therapeutic Targets EGFR, EpCAM, Tissue Factor, and TROP2 in Triple-Negative Breast Cancer.International journal of molecular sciences · 2025Article
- Serous Ovarian Carcinoma: Detailed Analysis of Clinico-Pathological Characteristics as Prognostic Factors.Cancers · 2024Article
- The relationship of lifetime history of depression on the ovarian tumor immune microenvironment.Brain, behavior, and immunity · 2023Article
- Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases.Journal for immunotherapy of cancer · 2023Article
- Automated Lung Cancer Segmentation in Tissue Micro Array Analysis Histopathological Images Using a Prototype of Computer-Assisted Diagnosis.Journal of personalized medicine · 2023Article
- Advancements in Oncoproteomics Technologies: Treading toward Translation into Clinical Practice.Proteomes · 2023Review
- Combination of Tissue Microarray Profiling and Multiplexed IHC Approaches to Investigate Transport Mechanism of Nucleoside Analog Drug Resistance.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Article
- Cell graph neural networks enable the precise prediction of patient survival in gastric cancer.NPJ precision oncology · 2022Article
- Manual Construction of a Tissue Microarray using the Tape Method and a Handheld Microarrayer.Journal of visualized experiments : JoVE · 2022Article
- Acrolein contributes to human colorectal tumorigenesis through the activation of RAS-MAPK pathway.Scientific reports · 2021Article
- Article
- Validation of CanAssist Breast immunohistochemistry biomarkers on an automated platform and its applicability in tissue microarray.International journal of clinical and experimental pathology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Tissue microarray (TMA) is a recently implemented, high-throughput technology for the analysis of molecular markers in oncology. This research tool permits the rapid assessment of a biomarker in thousands of tumor samples, using commonly available laboratory assays such as immunohistochemistry and in situ hybridization. Although introduced less than a decade ago, TMA has proven to be invaluable in the study of tumor biology, the development of diagnostic tests, and the investigation of oncologic biomarkers. This review describes the impact of TMA-based research in clinical oncology and its potential future applications. Technical aspects of TMA construction and the advantages and disadvantages inherent to this technology are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.